Asset Details
Do you wish to reserve the book?
Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
Do you wish to request the book?
Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
2017
Overview
Hepatic stellate cells (HSC) play a key role in the development of chronic liver disease (CLD). Liraglutide, well-established in type 2 diabetes, showed anti-inflammatory and anti-oxidant properties. We evaluated the effects of liraglutide on HSC phenotype and hepatic microvascular function using diverse pre-clinical models of CLD. Human and rat HSC were
in vitro
treated with liraglutide, or vehicle, and their phenotype, viability and proliferation were evaluated. In addition, liraglutide or vehicle was administered to rats with CLD. Liver microvascular function, fibrosis, HSC phenotype and sinusoidal endothelial phenotype were determined. Additionally, the effects of liraglutide on HSC phenotype were analysed in human precision-cut liver slices. Liraglutide markedly improved HSC phenotype and diminished cell proliferation. Cirrhotic rats receiving liraglutide exhibited significantly improved liver microvascular function, as evidenced by lower portal pressure, improved intrahepatic vascular resistance, and marked ameliorations in fibrosis, HSC phenotype and endothelial function. The anti-fibrotic effects of liraglutide were confirmed in human liver tissue and, although requiring further investigation, its underlying molecular mechanisms suggested a GLP1-R-independent and NF-κB-Sox9-dependent one. This study demonstrates for the first time that liraglutide improves the liver sinusoidal milieu in pre-clinical models of cirrhosis, encouraging its clinical evaluation in the treatment of chronic liver disease.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 14/1
/ 14/19
/ 38/77
/ 82/80
/ 96/106
/ Animals
/ Cell Proliferation - drug effects
/ Fibrosis
/ Hepatic Stellate Cells - drug effects
/ Hepatic Stellate Cells - metabolism
/ Humanities and Social Sciences
/ Humans
/ Liver
/ Liver Cirrhosis - drug therapy
/ Liver Cirrhosis - physiopathology
/ Male
/ Rodents
/ Science
